TY - JOUR
T1 - CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals
AU - Picton, Anabela C.P.
AU - Paximadis, Maria
AU - Chaisson, Richard E.
AU - Martinson, Neil A.
AU - Tiemessen, Caroline T.
N1 - Funding Information:
This work is based on the research supported by grants awards from South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation of South Africa, the South African Medical Research Council (Self-Initiated Research Grant), the Strategic Health Innovation Partnerships (SHIP) Unit of the South African Medical Research Council (a grantee of the Bill & Melinda Gates Foundation), the Poliomyelitis Research Foundation (PRF) and the Claude Leon Foundation (ACP: Postdoctoral Fellowship). The Longitudinal Study of HIV-Associated Lung Infections in Soweto (progressor group) was funded by the National Institutes of Health, USA (R01HL090312 and P30AI094189: R. E. Chaisson).
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - CXCR6 genetic variation was described for HIV-1-uninfected black (n = 41) and Caucasian (n = 40) South Africans. We also investigated the CXCR6 rs2234358 and rs2234355 single nucleotide polymorphisms in HIV-1 disease control in 124 HIV-1-infected drug-naïve black individuals [elite controllers (n = 11), viraemic controllers (VCs, n = 30), high viral load long-term nonprogressors (HVL LTNPs, n = 11) and progressors (n = 72)] compared to healthy controls (HCs; n = 232). The rs2234358-T allele was underrepresented in VCs (40.0%) compared to HCs (59%, P = 0.006), HVL LTNPs (72.7%, P = 0.012) and progressors (59%, P = 0.014). The rs2234358-TT genotype was underrepresented in VCs (7%) compared to progressors (32%; OR = 6.57, P = 0.006) and HCs (35%; OR = 7.18, P = 0.001, Pbonferroni = 0.034). The rs2234355-GA genotype was overrepresented in VCs (80%) compared to HCs (50.4%; OR = 0.25, P = 0.003) and progressors (29.17%; OR = 0.10, P = 3.8 × 10− 5, Pbonferroni = 0.001). The combination of rs2234355-GA in the absence of rs2234358-TT was overrepresented in VCs (80%) compared to HCs (32.6%, OR = 0.12, P = 1 × 10− 6, Pbonferroni = 3.4 × 10− 5) and to progressors (16.7%; OR = 0.05, P < 1 × 10− 8, Pbonferroni < 1 × 10− 7).
AB - CXCR6 genetic variation was described for HIV-1-uninfected black (n = 41) and Caucasian (n = 40) South Africans. We also investigated the CXCR6 rs2234358 and rs2234355 single nucleotide polymorphisms in HIV-1 disease control in 124 HIV-1-infected drug-naïve black individuals [elite controllers (n = 11), viraemic controllers (VCs, n = 30), high viral load long-term nonprogressors (HVL LTNPs, n = 11) and progressors (n = 72)] compared to healthy controls (HCs; n = 232). The rs2234358-T allele was underrepresented in VCs (40.0%) compared to HCs (59%, P = 0.006), HVL LTNPs (72.7%, P = 0.012) and progressors (59%, P = 0.014). The rs2234358-TT genotype was underrepresented in VCs (7%) compared to progressors (32%; OR = 6.57, P = 0.006) and HCs (35%; OR = 7.18, P = 0.001, Pbonferroni = 0.034). The rs2234355-GA genotype was overrepresented in VCs (80%) compared to HCs (50.4%; OR = 0.25, P = 0.003) and progressors (29.17%; OR = 0.10, P = 3.8 × 10− 5, Pbonferroni = 0.001). The combination of rs2234355-GA in the absence of rs2234358-TT was overrepresented in VCs (80%) compared to HCs (32.6%, OR = 0.12, P = 1 × 10− 6, Pbonferroni = 3.4 × 10− 5) and to progressors (16.7%; OR = 0.05, P < 1 × 10− 8, Pbonferroni < 1 × 10− 7).
KW - CXCR6
KW - HIV-1 control
KW - Haplotypes
KW - Single nucleotide polymorphisms
UR - http://www.scopus.com/inward/record.url?scp=85018495430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018495430&partnerID=8YFLogxK
U2 - 10.1016/j.clim.2017.04.006
DO - 10.1016/j.clim.2017.04.006
M3 - Article
C2 - 28428094
AN - SCOPUS:85018495430
SN - 1521-6616
VL - 180
SP - 69
EP - 79
JO - Clinical Immunology
JF - Clinical Immunology
ER -